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REQUIRED OUTCOMES REPORTING
TO SCTOD BEGINS THIS MONTH
Beginning this month, hematopoi-
etic cell transplant centers must report
treatment outcomes for all related and
unrelated allogeneic blood and mar-
row transplants, if the donor or recipi-
ent is in the United States. The Center
for International Blood and Marrow
Transplant Research (CIBMTR) data col-
lection forms and electronic systems
have been revised to accommodate
the federally mandated requirements.
Transplant centers have been in-
formed about the inauguration of a
Stem Cell Therapeutic Outcomes Data-
base (SCTOD) required by the C. W. Bill
Young Transplant Program, which was
enacted in December 2005. The CIB-
MTR has been awarded the federal
contract to maintain the SCTOD and, in
collaboration with the National Mar-
row Donor Program (NMDP), has ex-
panded its data collection forms to in-
clude the necessary data. The TED
(Transplant Essential Data) forms have
been revised in collaboration with the
European Group for Blood and Mar-
row Transplantation. The database will
be used for evaluation of the program’s
operations, including federally required
research such as analyses of transplant
center-specific outcomes and optimal
registry/cord blood bank size.
“The CIBMTR will continue to collect
data for scientific research, both at the
TED level and comprehensive research
report forms on a subset of allogeneic
and autologous transplants,” said Mary
Horowitz, MD, MS, chief scientific direc-
tor of the CIBMTR. “Although these activ-
ities are not part of the SCTOD, we have
taken advantage of the many changes
required to implement the SCTOD to
make some additional changes that we
think will significantly enhance our re-
search program and assist centers who
participate in that program.”
The CIBMTR and NMDP have harmo-
nized their respective Research Report
Forms into a single set of forms. The
CIBMTR and NMDP also have devel-
oped an overall data management
plan that includes electronic data sub-
mission of the TED forms and the har-
monized research forms, a combined
audit program, and combined data
submission policies and procedures.
Centers will no longer submit data to
both the NMDP and CIBMTR. Each cen-
ter is receiving a packet of information
that provides further details about the
SCTOD and how it impacts their center.
Included in the packet will be sample
copies of the TED forms and the har-
monized research forms.
ASBMT COMMENTS ON MEDICARE
PAYMENTS FOR CLINICAL TRIALS
A revision of federal policies on reim-
bursement of treatment for Medicare
patients in clinical trails has been pro-
posed by the Centers for Medicare and
Medicaid Services (CMS). ASBMT, to-
gether with the National Marrow Donor
Program, has submitted comments.
The current reimbursement policy, in
effect since 2000, has Medicare paying
for patient care services within clinical
trials that otherwise would be reim-
bursed outside of clinical trials. This overall
policy would not change under the pro-
posed new rules, but there would be a
variety of additional requirements.
The comments submitted by ASBMT
offered general support for the revisions,
but raised several concerns about an ex-
clusion from studies of Medicare partici-
pants younger than 65, an exclusion of
self certification and IND-exempt studies,
requirements for the publication of
flawed studies or the premature results of
studies, and the absence of a provision to
“grandfather” patients currently enrolled
in clinical trials.
CMS is expected to publish its final
rules by July 9.
CONFERENCE READIES CENTERS
FOR RADIATION EMERGENCIES
A one-day conference will address
ways that BMT centers and personnel
can prepare for radiation/nuclear
emergencies. To be held Sept. 25 in
Bethesda, Md., the conference is be-
ing organized by the Radiation Injury
Treatment Network (RITN), a cooper-
ative effort of the National Marrow
Donor Program and ASBMT.
The conference will provide an
overview of the impact and medical
challenges that would arise after a
radiological accident or the detona-
tion of a nuclear bomb within the
United States borders. Presentations
will include assessments of the cur-
rent threat and a review of possible
scenarios. In-depth information on
the medical complications of acute
radiation syndrome and its impact on
vital organs will be discussed.
Speakers will include Brooke Bud-
demeier; Nelson Chao, MD; C. Nor-
man Coleman, MD; Theodor Flied-
ner, MD; Martin Hauer-Jensen, MD;
Viktor Meineke, MD; Michael Rob-
bins, PhD; and Alla Shapiro, MD.
The conference hours will be
8:30 a.m. to 5:00 p.m. at the Mar-
riott Bethesda Hotel, 5151 Pooks
Hill Road.
BLOOD STEM CELL TRANSPLANTS
EXCEED 16,000 YEARLY IN U.S.
Currently more than 16,000 hema-
topoietic stem cell transplants are per-
formed annually in the United States,
according to estimates from the Cen-
ter for International Blood and Mar-
row Transplant Research (CIBMTR).
Based on data submitted by partici-
pating transplant centers, the CIBMTR
estimates that the numbers of trans-
plants in 2005 were:
Autologous – 10,000
Related allogeneic – 3,500
Unrelated allogeneic – 2,250
Cord blood – 550
Detailed information about trans-
plant indications, recipient age, graft
sources, transplant regimens and out-
comes can be found on the CIBMTR
Web site at www.cibmtr.org.
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